The Multicenter Prospective Randomized Controlled Trial Evaluating Efficacy of Pharmacological Approaches to Improve Long-Term Outcome of Catheter Ablation for Atrial Fibrillation: Kansai Plus Atrial Fibrillation (KPAF) trial - KPAF trial

Kyoto University Graduate School of Medicine0 个研究点目标入组 2,000 人开始时间: 2011年8月8日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) Patients who are intolerant for ATP or antiarrhythmic drugs (Vaughan Williams class I or III), including those in acute phase of intracranial bleeding and those with severe bronchial asthma, severe vasospastic angina, substantial bradycardia, a history of allergy for ATP or antiarrhythmic drugs or a history of severe adverse effect of ATP or antiarrhythmic drugs. 2) Patients equal or younger than 20 years and those equal or older than 80years 3) Patients who are unable to be followed in an out-patient clinic for one year 4) Patients with renal insufficiency (serum creatinine >=2.0mg/dl or hemodialysis) 5) Patients with NYHA class IV heart failure 6) Left ventricular ejection fraction < 40% 7) Left atrial diameter > 55mm 8) Very long-lasting (>=5years) persistent atrial fibrillation 9) Patients ineligible for optimal anticoagulant therapy 10) Patients with a history of myocardial infarction within the past 6 months 11) Patients with a history of open heart surgery 12) Patients with a planned open heart surgery 13) Patients with severe valve heart disease 14) Patients unwilling to sign the consent form for participation 15) When the attending physician are unwilling to enroll the patient in the study 16) When the attending physician consider inappropriate to enroll the patient in the study

发起方

Kyoto University Graduate School of Medicine